Literature DB >> 28262616

Protective effects of aloperine on monocrotaline-induced pulmonary hypertension in rats.

Fan Wu1, Yinju Hao1, Jiamei Yang1, Wanxia Yao1, Yanping Xu2, Lin Yan3, Yang Niu4, Tao Sun5, Jianqiang Yu6, Ru Zhou7.   

Abstract

Pulmonary hypertension (PH) is serious, fatal disease which is promoted by oxidative stress. Aloperine have antioxidation effects, which effects on pulmonary arteries remain unclear. Therefore, this study is designed to investigate whether aloperine has protective effects on PH induced by monocrotaline and whether these effects are associated with oxidative stress. PH was induced by monocrotaline (60mg/kg), and subsequently oral administration of aloperine (25, 50, 100mg/kg/day). At the end of the experiment, hemodynamic, pathomorphologic, electrocardiographic and echocardiographic data from the rats were obtained. At same time, oxidative stress biomarkers (superoxide dismutase, malonyldialdehyde, catalase, glutathione peroxidase, total antioxidant capacity) and the protein expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX)-2, NOX-4 in the lung of rat has been detected. The result shows that aloperine treatment showed significantly improvement in hemodynamic, pathomorphologic, electrocardiographic and echocardiographic data. Moreover, aloperine treatment can alleviate the changes of oxidative stress biomarkers and suppress the expression levels of NOX-2, NOX-4. In summary, this study indicates that aloperine have protective effects on monocrotaline-induced PH. And these effects may be related to inhibit oxidative stress.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Aloperine; Monocrotaline; NOX-2; NOX-4; Oxidative stress; Pulmonary hypertension

Mesh:

Substances:

Year:  2017        PMID: 28262616     DOI: 10.1016/j.biopha.2017.02.033

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

1.  Beneficial effects of fenofibrate in pulmonary hypertension in rats.

Authors:  Palak Galhotra; Pankaj Prabhakar; Himanshu Meghwani; Soheb A Mohammed; Sanjay Kumar Banerjee; Sandeep Seth; Milind P Hote; K H Reeta; Ruma Ray; Subir Kumar Maulik
Journal:  Mol Cell Biochem       Date:  2018-05-14       Impact factor: 3.396

2.  In Vitro Antitumor Activity of Aloperine on Human Thyroid Cancer Cells through Caspase-Dependent Apoptosis.

Authors:  Ying-Ray Lee; Shu-Hsin Chen; Ching-Yen Lin; Wen-Ying Chao; Yun-Ping Lim; Hui-I Yu; Chieh-Hsiang Lu
Journal:  Int J Mol Sci       Date:  2018-01-21       Impact factor: 5.923

3.  Aloperine Protects Mice against Bleomycin-induced Pulmonary Fibrosis by Attenuating Fibroblast Proliferation and Differentiation.

Authors:  Wanling Yin; Jing Han; Zhijun Zhang; Zaomu Han; Siyuan Wang
Journal:  Sci Rep       Date:  2018-04-19       Impact factor: 4.379

4.  Protective Effects of 18β-Glycyrrhetinic Acid on Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats.

Authors:  Min Zhang; Zhi Chang; Fang Zhao; Peng Zhang; Yin-Ju Hao; Lin Yan; Ning Liu; Jun-Li Wang; Lei Bo; Ping Ma; Wei Zhou; Xuan Ma; Qing-Bin Xu; Ru Zhou
Journal:  Front Pharmacol       Date:  2019-01-22       Impact factor: 5.810

5.  Autophagy Modulation in Human Thyroid Cancer Cells following Aloperine Treatment.

Authors:  Hui-I Yu; Hui-Ching Shen; Shu-Hsin Chen; Yun-Ping Lim; Hsiang-Hsun Chuang; Tsai-Sung Tai; Fang-Ping Kung; Chieh-Hsiang Lu; Chia-Yi Hou; Ying-Ray Lee
Journal:  Int J Mol Sci       Date:  2019-10-25       Impact factor: 5.923

6.  Aquaporin-2 expression in the kidney and urine is elevated in rats with monocrotaline-induced pulmonary heart disease.

Authors:  Shao Ouyang; Wei Chen; Gaofeng Zeng; Changcheng Lei
Journal:  J Int Med Res       Date:  2020-01       Impact factor: 1.671

7.  Formononetin attenuates monocrotaline‑induced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats.

Authors:  Changhong Cai; Yijia Xiang; Yonghui Wu; Ning Zhu; Huan Zhao; Jian Xu; Wensheng Lin; Chunlai Zeng
Journal:  Mol Med Rep       Date:  2019-10-30       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.